Amgen's Blincyto puts leukemia patients in remission; Biogen confirms second PML case in Tecfidera patients;

> In a Phase II study, a "clinically meaningful" number of relapsed or refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (ALL) patients taking Amgen's ($AMGN) Blincyto experienced complete remission or complete remission with partial hematological recovery. Release | Story

> Biogen ($BIIB) has confirmed the second case of rare brain disease progressive multifocal leukoencephalopathy (PML) among Tecfidera patients. More

> AstraZeneca ($AZN) has entered an agreement with Kyowa Hakko Kirin for an exclusive option to market current candidate drug benralizumab for asthma and COPD in Japan. Release

> Germany's price watchdog has reassessed the data on Novartis' ($NVS) MS pill Gilenya, and it's now recommending the treatment for more patients. Report

And Finally... Scientists believe they can use smartphones to identify people suffering depressive symptoms with 87% accuracy. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.